Liquidia Corporation (NASDAQ: LQDA)...
LQDA Stock Surges After $380.7 Million Liquidia Settlement: What Investors Need to Know
read more
Biotech
Artelo Biosciences (NASDAQ: ARTL): Six Months Later, the ART27.13 Story Just Took an Unexpected Turn
When we last looked at Artelo...
Artelo Biosciences, Inc.
ARTL
$2.70
1.46%
Marketcap
1.48M
Volume
$12,300.00
Shares
547,774
Range
$2.70 - $2.76
52 Week Range
$2.70 - $179.19
Breakout Alert: ARTL
ARTL Stock Alert: Is Artelo...
Mangoceuticals (MGRX): A Low Float Stock on the Verge of a Short Squeeze?
In the fast-moving world of biotech...
Argo Living Soils (OTC: ARLSF): A Groundbreaking Opportunity in the Booming Sustainable Agriculture Market
Could ARLSF hit $1.00 today? Let's...
CYBIN (CYBN) ISSUED A BUY RATING WITH A 1,539% UPSIDE!
Good Morning Traders, Cybin CYBN...
Coeptis Therapeutics Could Revolutionize The Treatment of Cancer
Small Cap Exclusive is proud to...
“OKYO Pharma Limited: A Pioneer in the Pharmaceutical Industry”
In today's fast-paced world, the field...
Coeptis Therapeutics Could Go To The Moon This Week!
WEXFORD, Pa., May 10, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that research involving its SNAP-CAR technology was detailed in a peer-reviewed article published in the peer-reviewed journal, Nature Communications. SNAP-CAR is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors